Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,840 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06743867RecruitingPhase 1
Chemotherapy mist for cancer spread in the belly
This trial tests a new way to give chemotherapy directly into the belly as a fine mist (called PIPAC) for people whose cancer has spread there. The goal is to see if it’s safe and helps shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07549958RecruitingPhase 1
Gemcitabine with or without Pitavastatin for Advanced Pancreatic Cancer
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
Orange, CaliforniaAges 18 years+ - NCT07548476Recruiting
Acupuncture and exercise for nerve pain from cancer treatment
This study tests whether adding acupuncture and exercise can help prevent or reduce nerve pain, numbness, or tingling caused by a cancer treatment called EV-Pembro (a drug combination for bladder cancer). It may help you stay active and feel better during treatment.
Boston, MassachusettsAges 18 years+ - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT07518147RecruitingPhase 3
BL-M05D1 for advanced stomach cancer after first treatment
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07523529RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Shenzhen, GuangdongAges 18–75 - NCT07524140RecruitingPhase 1
Study of ZE94-0605 for advanced solid tumors
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
Kogarah, New South WalesAges 18 years+ - NCT07518160RecruitingPhase 2
JS212 and JS111 for advanced lung cancer with EGFR mutations
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07510828RecruitingPhase 1/Phase 2
CAR-NK cells for advanced solid tumors
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07500220RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for advanced liver cancer
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07492628RecruitingPhase 1
Dual-target cell therapy for advanced bladder cancer
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
Shenzhen, GuangdongAges 18–75 - NCT07487896RecruitingPhase 3
YL201 vs. chemo for advanced esophageal cancer after first treatment
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
Anqing, AnhuiAges 18 years+ - NCT07484022RecruitingPhase 1
A new drug added to standard treatment for advanced bladder cancer
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
Duarte, CaliforniaAges 18 years+ - NCT07481383RecruitingPhase 1
Implant device for chemo delivery in advanced pancreatic cancer
This trial tests an implantable device that delivers chemotherapy (gemcitabine) directly to pancreatic tumors. It may offer a new treatment option for people with non-metastatic, advanced pancreatic cancer that cannot be surgically removed.
Ann Arbor, MichiganAges 18 years+ - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07478523RecruitingPhase 2
FAPI-PET scan for initial screening of pancreatic and bile duct cancers
This trial tests a new imaging method called FAPI-PET to see if it can better detect pancreatic and bile duct cancers at an early stage. It may help doctors decide on the best treatment plan for you.
PessacAges 18 years+ - NCT07469982RecruitingPhase 1
Study of SY-9453 for advanced solid tumors
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
ShanghaiAges 18 years+ - NCT05205850RecruitingPhase 1/Phase 2
RC118 for solid cancers with Claudin 18.2 on tumor cells
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Little Rock, ArkansasAges 18 years+ - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT04762641RecruitingPhase 1
First-dose safety study of ABL503 for advanced cancers
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Duarte, CaliforniaAges 18 years+ - NCT07429487Recruiting
Smartwatch activity tracking for fatigue after chemo
This study uses a smartwatch to track your physical activity and see if it helps reduce tiredness after finishing chemotherapy. It is for people who finished treatment for certain cancers less than 3 months ago.
NiceAges 18–75 - NCT07417488RecruitingPhase 1
Vaccine therapy for advanced colorectal and small bowel cancer
This trial tests a vaccine therapy for people with advanced colorectal or small bowel cancer that has spread or can't be removed. The vaccine targets a protein found on cancer cells to help your immune system fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,840 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.